Disease · MONDO_0005027

epilepsy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. epilepsy. Diseases, record MONDO_0005027. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005027

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: epilepsy; Open Targets
Open Targets ID: MONDO_0005027; Open Targets
Other names: EF - Epileptic fit, EP - Epilepsy, EPILEP NEC W/O INTR EPIL, EPILEP NOS W/O INTR EPIL, EPILEPSY NEC W INTR EPIL, EPILEPSY NOS W INTR EPIL, Epilectic attack, NOS, Epilepsy (disorder), Epilepsy NOS, Epilepsy NOS (disorder), Epilepsy and recurrent seizures, Epilepsy, unspecified, Epilepsy, unspecified, with intractable epilepsy, Epilepsy, unspecified, without mention of intractable epilepsy, Epileptic, Epileptic Seizure, Epileptic attack, Epileptic attack, NOS, Epileptic convulsions, Epileptic convulsions, NOS, Epileptic disorder, Epileptic disorder, NOS, Epileptic fit, Epileptic fits, Epileptic fits, NOS, Epileptic seizure (finding), Epileptic seizures, Epileptic seizures, NOS, Generalised convulsion, Generalised fit, Generalised seizure, Generalized convulsion, Generalized fit, Generalized seizure, Generalized seizure (finding), Other forms of epilepsy, Other forms of epilepsy (disorder), Other forms of epilepsy NOS, Other forms of epilepsy NOS (disorder), Other forms of epilepsy and recurrent seizures, Other forms of epilepsy, with intractable epilepsy, Other forms of epilepsy, without mention of intractable epilepsy, Seizure disorder (disorder), [X]Other epilepsy, [X]Other epilepsy (disorder), seizure disorder; Open Targets
Disease Ontology: DOID:1826; Disease Ontology
MeSH: D004827; MeSH
NCI Thesaurus: C3020; NCI Thesaurus
Highest stage of its drugs: Approval, for 60 of its 139 drugs, from ATC, ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs139

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LEVETIRACETAM	CHEMBL1286	Small molecule	Approval	ATC, DailyMed, EMA Human Drugs, PMDA and TTD	177	37	37	Drugs and targets
LAMOTRIGINE	CHEMBL741	Small molecule	Approval	ATC, DailyMed, PMDA and TTD	123	27	27	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Approval	ATC and ClinicalTrials.gov	25	23	23	Drugs and targets
TOPIRAMATE	CHEMBL220492	Small molecule	Approval	ATC, DailyMed, PMDA and TTD	115	22	22	Drugs and targets
VALPROIC ACID	CHEMBL109	Small molecule	Approval	ATC, DailyMed and TTD	51	18	17	Drugs and targets
BRIVARACETAM	CHEMBL607400	Small molecule	Approval	ATC, EMA Human Drugs, FDA and PMDA	25	18	18	Drugs and targets
CARBAMAZEPINE	CHEMBL108	Small molecule	Approval	ATC, DailyMed and TTD	29	16	16	Drugs and targets
PERAMPANEL	CHEMBL1214124	Small molecule	Approval	ATC and DailyMed	16	14	14	Drugs and targets
DIAZEPAM	CHEMBL12	Small molecule	Approval	DailyMed and TTD	18	12	12	Drugs and targets
LACOSAMIDE	CHEMBL58323	Small molecule	Approval	ATC, DailyMed, EMA Human Drugs, PMDA and TTD	18	11	11	Drugs and targets

1 to 10 of 139

See all 139 drugs

Targets135

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SCN8A	Sodium channel alpha subunit	18	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor; Sodium channel protein type VIII alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6334	Drugs and targets
SCN10A	Sodium channel alpha subunit	17	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	17	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	17	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	17	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	17	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	17	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	17	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	17	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6332	Drugs and targets
SCN9A	Sodium channel alpha subunit	17	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6335	Drugs and targets

1 to 10 of 135

See all 135 targets

Trials240

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 11 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01682681	An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy		1,234	2013-08-16	Epilepsy	TOPIRAMATE	Its record names the disease	ClinicalTrials.gov
NCT01243177	Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older	Phase 3	888	2016-02-23	Epilepsy, Monotherapy	CARBAMAZEPINE, LACOSAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00175916	Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy	Phase 3	853	2020-07-16	Epilepsy	BRIVARACETAM	Its record names the disease	ClinicalTrials.gov
NCT01339559	Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy	Phase 3	767	2020-06-04	Epilepsy	BRIVARACETAM	Its record names the disease	ClinicalTrials.gov
NCT00150800	This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment	Phase 3	668	2018-12-05	Epilepsy	BRIVARACETAM	Its record names the disease	ClinicalTrials.gov
NCT00235755	Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy	Phase 3	539	2011-11-07	Seizures	EZOGABINE	Its record names the disease	ClinicalTrials.gov
NCT00504881	Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy	Phase 3	480	2017-03-17	Epilepsy	BRIVARACETAM	Its record names the disease	ClinicalTrials.gov
NCT01832038	Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures	Phase 3	473	2020-08-13	Epilepsy, Partial-onset Seizures	LACOSAMIDE	Its record names the disease	ClinicalTrials.gov
NCT01954121	Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures	Phase 3	436	2016-08-11	Epilepsy, Partial Seizures	CARBAMAZEPINE, LEVETIRACETAM	Its record names the disease	ClinicalTrials.gov
NCT03373383	Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy	Phase 2	411	2021-04-09	Drug-resistant Epilepsy, Focal-Onset Seizures	PADSEVONIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 240

See all 240 trials

Comparisons in its trials91

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): Number of Subjects Who Withdraw From the Study Due to a Treatment-emergent Adverse Event (AE) During the Treatment Phase (up to 113 Weeks)	47 of 444	69 of 442	886	NCT01243177	Trial comparisons
Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): Number of Subjects With at Least One Treatment-emergent Adverse Event (AE) During the Treatment Phase (up to 113 Weeks)	328 of 444	332 of 442	886	NCT01243177	Trial comparisons
Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): Number of Subjects With at Least One Treatment-emergent Serious Adverse Event (SAE) During the Treatment Phase (up to 113 Weeks)	32 of 444	43 of 442	886	NCT01243177	Trial comparisons
Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): serious adverse events	36 of 444	46 of 442	886	NCT01243177	Trial comparisons
Brivaracetam vs Placebo: serious adverse events	20 of 359	9 of 121	480	NCT00504881	Trial comparisons
Levetiracetam (Safety Set) vs Carbamazepine-IR (Safety Set): serious adverse events	9 of 218	11 of 215	433	NCT01954121	Trial comparisons
Rufinamide vs Placebo: deaths from any cause	0 of 176	0 of 180	356	NCT00334958	Trial comparisons
Rufinamide vs Placebo: serious adverse events	6 of 176	7 of 180	356	NCT00334958	Trial comparisons
Vimpat + Na Channel Blocking AED vs Vimpat + Non-Na Channel Blocking AED: serious adverse events	1 of 153	6 of 158	311	NCT01673282	Trial comparisons
Melatonin vs Placebo: deaths from any cause	0 of 137	0 of 138	275	NCT05439876	Trial comparisons

1 to 10 of 91

See all 91 comparisons in its trials

Papers from its trials101

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41053929	RESULT	1	PubMed
40737960	RESULT	1	PubMed
40650667	RESULT	1	PubMed
37973662	RESULT	1	PubMed
37597326	RESULT	1	PubMed
36529709	RESULT	1	PubMed
36176044	RESULT	2	PubMed
35196395	RESULT	1	PubMed
34246118	RESULT	1	PubMed
34218211	RESULT	3	PubMed

1 to 10 of 101

See all 101 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005027

GET https://conductscience.org/api/diseases/v1/MONDO_0005027/drugs?page=2

API reference For AI assistants